肺纤维化治疗

Search documents
老药新用!黄波团队发现碳酸锂可逆转肺纤维化,清除“瘢痕制造者”肌成纤维细胞
生物世界· 2025-09-23 08:30
肺纤维化 ( Pulmonary Fibrosis,PF ) 是一种以肺泡结构破坏和胶原沉积为特征的致命性疾病。患者一旦确诊,往往面临不可逆的肺功能下降和极高的死亡风 险。目前临床获批的两款药物 (吡非尼酮与尼达尼布) 只能延缓病情,却无法真正逆转已形成的纤维化病灶。 长期以来,如何清除驱动纤维化的 " 罪魁祸首 "—— 肌成纤维细胞 ,一直是医学界面临的最大挑战。这类细胞不仅是胶原蛋白的主要来源,还具备 " 自我激 活、无限增殖和抗凋亡 " 的顽固特性,甚至能通过分泌 TGF-β 持续放大自身活化信号,形成恶性循环。正是这些长期盘踞在病灶的 " 瘢痕制造者 " ,构成了肺 纤维化难以治愈、难以逆转的核心障碍。 编辑丨王多鱼 排版丨水成文 近日,华中科技大学基础医学院 、 中国医学科学院基础医学研究所 黄波 教授团队在 Immunity & Inflammation 期刊 发表了题为 : Lithium carbonate induces myofibroblast necroptosis to reverse pulmonary fibrosis 的研究论文。 该研究发现,临床常用的 情绪稳定剂 —— 碳酸 ...
“一喷一吸”就能治疗肺纤维化?
Ke Ji Ri Bao· 2025-06-30 23:44
Core Insights - The article discusses the development of a novel treatment strategy for pulmonary fibrosis called "exosome nebulization therapy," which has been researched by a collaborative team from Tsinghua University and other institutions [1][5][7] Group 1: Health Issues Related to Pulmonary Fibrosis - Pulmonary fibrosis is characterized by the gradual scarring of lung tissue, leading to severe breathing difficulties and is often referred to as "the cancer that does not die" due to its chronic and progressive nature [2][3] - The disease can be classified into two main types: idiopathic pulmonary fibrosis, which has an unknown cause and poor prognosis, and secondary pulmonary fibrosis, which has identifiable triggers such as infections or autoimmune diseases [2][3] Group 2: Current Treatment Limitations - Current treatments for pulmonary fibrosis, such as pirfenidone and nintedanib, can only stabilize the condition and delay progression but cannot reverse fibrosis or improve survival rates [5][7] - Lung transplantation remains the only curative option, but its application is limited by donor shortages and postoperative complications [5][7] Group 3: Exosome Nebulization Therapy - Exosome nebulization therapy utilizes exosomes derived from human umbilical cord mesenchymal stem cells, which contain various proteins and RNAs that play crucial roles in cellular communication and immune response [5][6] - The therapy involves nebulizing these exosomes into fine particles for inhalation, allowing for targeted delivery to lung lesions, enhancing treatment precision compared to traditional stem cell therapies [6][7] - Animal studies have shown that this therapy significantly improves pulmonary fibrosis progression, with survival rates in treated mice increasing from 20% to 80% [6][7] Group 4: Clinical Trials and Future Directions - Initial clinical trials involving 24 patients demonstrated good safety and significant improvements in lung function and respiratory health for those receiving combined treatment with exosome nebulization and standard medication [7][8] - Despite the promising results, further large-scale Phase II and III clinical trials are necessary to fully validate the efficacy of exosome therapy [8] - Regulatory challenges exist in approving exosome therapy as a commercial drug due to its complex composition, necessitating the development of a more flexible evaluation system for its application [8]